Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2010

View Archived Issues

Cornerstone and Alitair collaborate on drug development for respiratory diseases

Ajinomoto claims new inhibitors of IL-12/IL-23 production

ArQule discloses new FGFR inhibitors

Taisho discovers new DP2 receptor antagonists

Japanese researchers describe new KIF11 inhibitors

IGFBP-7 mediates oncogene-induced senescence in papillary thyroid carcinoma

DAB2IP gene SNP correlates with susceptibility to abdominal aortic aneurism

Regadenoson SPECT is safe and tolerated in patients with CKD and ESRD

TBR-652 exhibits potent anti-HIV activity in phase II trial

Nanobin encapsulation improves therapeutic efficacy of As2O3 in solid tumors

Lexicon reacquires rights to several serotonin synthesis inhibitors from Symphony Icon

Merck & Co. identifies new gamma-secretase modulators

Mallinckrodt claims novel diagnostic agents for renal disorders

FDA clears first-in-human trial of N-6022

Seattle Genetics and Genentech expand antibody-drug conjugate agreement

Diamyd receives upfront payment from OMJP under Diamyd collaboration

Oxygen signs CRADA with U.S. navy to study decompression sickness therapy

FusoGen presents phase IIb data on sifuvirtide in HIV

Pharmachem Laboratories offers to acquire all assets from Forbes Medi-Tech

First patient receives treatment in phase Ib expansion trial of CUDC-101

Patient enrollment advances ahead of schedule in phase III Probuphine trial

Northwest reports phase I/II data on DCVax-Brain personalized immune therapy

MiddleBrook Pharmaceuticals completes sale of assets to Victory Pharma

Mitsubishi Tanabe transfers Kerlong marketing rights to sanofi-aventis

Taisho Pharma discontinues development of TS-022 for atopic dermatitis with pruritus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...